Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018


January 7, 2013
154 Pages - SKU: GMD4939667
License type:
Table of Contents Search inside this report Related Reports
Countries covered: Norway
Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Summary

Global Markets Direct’s new report, ”Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018” provides key market data on the Norway In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope
  • Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
  • Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
  • 2011 company shares and distribution shares data for each of the seven market categories.
  • Global corporate-level profiles of key companies operating within the Norway In Vitro Diagnosticsmarket.
  • Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Ortho-Clinical Diagnostics Inc., bioMerieux S.A., Beckman Coulter, Inc. and others.
Reasons to buy
  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Norway In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 In Vitro Diagnostics In Norway
3.1 In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, 2004-2018
3.2 In Vitro Diagnostics, Norway, Company Share (2010-2011)
4 Clinical Chemistry In Norway
4.1 Clinical Chemistry Overall Revenue, (2004-2018)
4.1.1 Clinical Chemisty Analyzers, Revenue (2004-2018)
4.1.2 Urine Analysis, Revenue (2004-2018)
4.2 Clinical Chemistry Distribution Share (2010-2011)
4.3 Clinical Chemistry, Norway, Company Share (2010-2011)
5 Genetic Testing In Norway
5.1 Genetic Testing Overall Revenue, (2004-2018)
5.2 Genetic Testing Distribution Share (2010-2011)
5.3 Genetic Testing, Norway, Company Share (2010-2011)
6 Haematology In Norway
6.1 Haematology Overall Revenue, (2004-2018)
6.1.1 Haematology Reagents, Revenue, (2004-2018)
6.1.2 Immunohaematology, Revenue (2004-2018)
6.1.3 Haemostasis, Revenue (2004-2018)
6.1.4 Haematology Rapid Tests, Revenue (2004-2018)
6.1.5 Haematology Cell Counters, Revenue (2004-2018)
6.2 Haematology Distribution Share (2010-2011)
6.3 Haematology, Norway, Company Share (2010-2011)
7 Histology And Cytology In Norway
7.1 Histology And Cytology Overall Revenue, (2004-2018)
7.2 Histology And Cytology Distribution Share (2010-2011)
7.3 Histology And Cytology, Norway, Company Share (2010-2011)
8 Immuno Chemistry In Norway
8.1 Immuno Chemistry Overall Revenue, (2004-2018)
8.1.1 Disease Specific Immunochemistry, Revenue (2004-2018)
8.1.2 Drugs of Abuse / Toxicology, Revenue (2004-2018)
8.1.3 Endocrinology Tests, Revenue (2004-2018)
8.1.4 Immunochemistry Rapid Tests, Revenue (2004-2018)
8.1.5 Therapeutic Drug Monitoring, Revenue (2004-2018)
8.1.6 Immunochemistry Analyzers, Revenue (2004-2018)
8.2 Immuno Chemistry Distribution Share (2010-2011)
8.3 Immuno Chemistry, Norway, Company Share (2010-2011)
9 Infectious Immunology In Norway
9.1 Infectious Immunology Overall Revenue, (2004-2018)
9.1.1 Infectious Immunology Rapid Tests, Revenue (2004-2018)
9.2 Infectious Immunology Distribution Share (2010-2011)
9.3 Infectious Immunology, Norway, Company Share (2010-2011)
10 Microbiology Culture In Norway
10.1 Microbiology Culture Overall Revenue, (2004-2018)
10.1.1 Microbiology Analyzers, Revenue (2004-2018)
10.2 Microbiology Culture Distribution Share (2010-2011)
10.3 Microbiology Culture, Norway, Company Share (2010-2011)
11 Overview of Key Companies in Norway In Vitro Diagnostics Market
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 Company Overview
11.2 Siemens Healthcare
11.2.1 Company Overview
11.3 Abbott Laboratories
11.3.1 Company Overview
11.4 Ortho-Clinical Diagnostics Inc.
11.4.1 Company Overview
11.5 bioMerieux S.A.
11.5.1 Company Overview
11.6 Beckman Coulter, Inc.
11.6.1 Company Overview
11.7 Sysmex Corporation
11.7.1 Company Overview
11.8 Bio-Rad Laboratories, Inc.
11.8.1 Company Overview
11.9 Becton, Dickinson and Company
11.9.1 Company Overview
11.10 Alere Inc.
11.10.1 Company Overview
11.11 Mindray Medical International Limited
11.11.1 Company Overview
11.12 Danaher Corporation
11.12.1 Company Overview
11.13 Qiagen N.V.
11.13.1 Company Overview
11.14 DiaSorin S.p.A
11.14.1 Company Overview
11.15 Diagnostica Stago, Inc.
11.15.1 Company Overview
11.16 Thermo Fisher Scientific Inc.
11.16.1 Company Overview
11.17 PerkinElmer, Inc.
11.17.1 Company Overview
11.18 Horiba, Ltd.
11.18.1 Company Overview
11.19 Gen-Probe Incorporated
11.19.1 Company Overview
11.20 Immucor, Inc.
11.20.1 Company Overview
11.21 Life Technologies Corporation
11.21.1 Company Overview
11.22 Grifols, S.A.
11.22.1 Company Overview
11.23 Cellestis Limited
11.23.1 Company Overview
11.24 Hologic, Inc.
11.24.1 Company Overview
12 Appendix
12.1 Global Markets Direct Research Methodology
12.2 Definitions of Markets Covered in the Report
12.2.1 In Vitro Diagnostics
12.3 Secondary Research
12.4 Primary Research
12.5 Models
12.6 Forecasts
12.7 Expert Panel Validation
12.8 Currency Conversion
12.9 Contact Us
12.10 Disclaimer
1.1 List of Tables
Table 1: In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018
Table 2: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Table 3: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Table 4: In Vitro Diagnostics, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 5: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 6: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 7: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 8: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 9: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 10: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 11: Clinical Chemistry, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 12: Clinical Chemistry, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 13: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 14: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 15: Genetic Testing, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 16: Genetic Testing, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 17: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 18: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 19: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 20: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 21: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 22: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 23: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 24: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 25: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 26: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 27: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 28: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 29: Haematology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 30: Haematology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 31: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 32: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 33: Histology And Cytology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 34: Histology And Cytology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 35: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 36: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 37: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 38: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 39: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 40: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 41: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 42: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 43: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 44: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 45: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 46: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 47: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 48: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 49: Immuno Chemistry, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 50: Immuno Chemistry, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 51: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 52: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 53: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 54: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 55: Infectious Immunology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 56: Infectious Immunology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 57: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 58: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 59: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 60: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 61: Microbiology Culture, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 62: Microbiology Culture, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018
Figure 2: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Figure 3: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Figure 4: In Vitro Diagnostics, Norway, Company Share (%), 2011
Figure 5: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 6: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 7: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 8: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 9: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 10: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 11: Clinical Chemistry, Norway, Company Share (%), 2011
Figure 12: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 13: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 14: Genetic Testing, Norway, Company Share (%), 2011
Figure 15: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 16: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 17: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 18: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 19: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 20: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 21: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 22: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 23: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 24: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 25: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 26: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 27: Haematology, Norway, Company Share (%), 2011
Figure 28: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 29: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 30: Histology And Cytology, Norway, Company Share (%), 2011
Figure 31: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 32: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 33: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 34: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 35: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 36: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 37: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 38: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 39: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 40: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 41: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 42: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 43: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 44: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 45: Immuno Chemistry, Norway, Company Share (%), 2011
Figure 46: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 47: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 48: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 49: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 50: Infectious Immunology, Norway, Company Share (%), 2011
Figure 51: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 52: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 53: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 54: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 55: Microbiology Culture, Norway, Company Share (%), 2011
Figure 56: Global Markets Direct Methodology

More Hematology & Oncology reports by Global Markets Direct

Chile In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 by Global Markets Direct
Chile In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 Summary Global Markets Direct’s new report, ”Chile In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to ...
United Arab Emirates In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 by Global Markets Direct
United Arab Emirates In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 Summary Global Markets Direct’s new report, ”United Arab Emirates In Vitro Diagnostics Investment Opportunities, ...
Finland In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 by Global Markets Direct
Finland In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 Summary Global Markets Direct’s new report, ”Finland In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to ...
Egypt In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 by Global Markets Direct
Egypt In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 Summary Global Markets Direct’s new report, ”Egypt In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to ...
See all reports like this >>

More Norway reports

D&B Country RiskLine Report: Norway by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: Norway by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report Norway January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Norway: Country Profile by MarketLine
INTRODUCTION This report provides a detailed analysis on Norway, providing an overview of its political, economic and business environment, represented both textually and in graph and ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Hematology & Oncology Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!